MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/hae.15098

Медицинская библиотека · Haemophilia : the official journal of the World Federation of Hemophilia · 2024

Efficacy and safety of a recombinant von Willebrand factor treatment in acquired von Willebrand syndrome in case of bleeding and surgical procedures.

Desprez Dominique, Pierre Léa, Hittinger Xavier, Babuty Antoine, Sattler Laurent, Ternisien Catherine, Herb Agathe, Trossaërt Marc, Gérout Anne-Cécile, Fouassier Marc, Wimmer Jordan, Feugeas Olivier, Drillaud Nicolas

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Acquired von Willebrand syndrome (AVWS) is a rare haemorrhagic disorder. The prophylaxis and treatment of bleeding before surgery are complex. Since 2018, a new recombinant VWF (rVWF) concentrate that contains no factor VIII (FVIII) but a high amount of high molecular weight VWF multimers has been available in France.

AIM: To describe the real-world experience of using rVWF in non-surgical bleeding and surgical procedures in patients with AVWS.

METHODS

Fifteen bleeding episodes in seven patients and 16 surgeries in 10 patients were retrospectively analysed in t French haemostasis centres.

RESULTS

During bleeding, the median number of infusions was only 1 (range 1-27) with a median loading dose of 58 IU/kg (range 17-116) rVWF and a total median dose of 65 IU/kg (range 35-1488) rVWF. Bleeding control was rated markedly effective in 73% (11/15) of the cases and ineffective in 27% (4/15). During surgeries, the median number of infusions was 3 (range 1-8) with a preoperative loading dose of 60 IU/kg (range 23-118) rVWF and a total median dose of 123 IU/kg (range 31-542). The overall clinical efficacy was qualified as excellent, good and poor (ISTH criteria) in respectively 7 (43%), 6 (38%) and 3 (19%) procedures. There was no accumulation of VWF or FVIII during postoperative monitoring. No thromboembolic events nor adverse events were reported.

CONCLUSION

This French 'real-world' experience shows that rVWF could be of interest in the treatment and prophylaxis of bleeding in patients with AVWS, with no clinically significant safety concern.

Для цитирования: Desprez Dominique, Pierre Léa, Hittinger Xavier, Babuty Antoine, Sattler Laurent, Ternisien Catherine, Herb Agathe, Trossaërt Marc, Gérout Anne-Cécile, Fouassier Marc, Wimmer Jordan, Feugeas Olivier, Drillaud Nicolas. Efficacy and safety of a recombinant von Willebrand factor treatment in acquired von Willebrand syndrome in case of bleeding and surgical procedures.. Haemophilia : the official journal of the World Federation of Hemophilia. 2024. DOI: 10.1111/hae.15098.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.